touchONCOLOGY talks to Jeffrey S Weber from the Laura and Isaac Perlmutter Cancer Cente and NYU Langone Medical Center about the limitations of ipilimumab for the treatment of resected stage III melanoma and how the findings of the CheckMate238 trial can improve the safety profile of this patient population.
1. What are the limitations of ipilimumab as adjuvant therapy in patients with resected stage III melanoma? (0:11)
2. What is the current prognosis for patients with resected stage III or IV melanoma? (1:28)
3. What are the aims of the CheckMate 238 study? (2:51)
4. What have been the efficacy findings of the study to date? (3:31)
5. How does the safety profile of nivolumab compare to that of ipilimumab in this patient population? (4:36)
Speaker disclosures: Jeffrey S Weber has nothing to disclose in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018.
Read our Insight coverage here.
Share this Video
Related Videos In Dermatological Cancer
Jason Luke, ESMO 2021: Efficacy and Safety Results from the KEYNOTE-716 Double-blind Phase III Trial
touchONCOLOGY joins Dr Jason Luke (UPMC Hillman Cancer Center, PA, USA) at ESMO 2021 to discuss the efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. Questions 1. Patients with high-risk stage II melanoma are at significant risk of recurrence after surgical resection – what treatment options do these patients currently have to […]
Evan Lipson, ASCO 2021: Relatlimab plus Nivolumab in Advanced Melanoma
TouchONCOLOGY got the chance to catch up with Dr Evan Lipson (Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA) around the RELATIVITY-047 study, which investigated the combined therapy of relatlimab plus nivolumab in patients with advanced melanoma. The abstract ‘Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III […]
Paolo A Ascierto,ESMO 2020 – The SEquential COMBo Immuno and Targeted therapy (SECOMBIT) study
Editorial board member, Dr Paolo A Ascierto, joins us at the Virtual 2020 ESMO Congress to discuss immunotherapy in BRAF-mutated metastatic melanoma and the major findings from the The SEquential COMBo Immuno and Targeted therapy (SECOMBIT) study. Questions What is the rationale for the combination of targeted and immunotherapy in the treatment of BRAF-mutated metastatic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!